“Breaking News: Apellis’ SYFOVRE Pegcetacoplan Receives Australian Approval for Treating Geographic Atrophy (GA)”
Exciting News in the World of Ophthalmology Introduction Apellis Pharmaceuticals, Inc. has recently made a groundbreaking announcement in the field of ophthalmology. The Therapeutic Goods Administration (TGA) has approved SYFOVRE® (pegcetacoplan) for the every-other-month treatment of adult patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) with an intact fovea. This approval marks…